Trial Profile
A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607-QIV(Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Children and Adolescents Aged 6 Months ~ 18 Years
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jul 2022
Price :
$35
*
At a glance
- Drugs NBP 607 QIV (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors SK Chemicals
- 16 Jul 2019 Results published in the Pediatric Infectious Disease Journal
- 07 Dec 2015 New trial record